Status:
COMPLETED
Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology
Lead Sponsor:
Pfizer
Conditions:
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Eligibility:
All Genders
50-99 years
Brief Summary
The main purpose of this study is to determine the prevalence of ATTR Cardiomyopathy among patients admitted due to Left Ventricular Hypertrophy (LVH) \>15mm of unknown etiology by using a 99mTc-trace...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patient signed inform consent.
- Males and Females.
- Age ≥50 years.
- Left ventricular hypertrophy (LVH) defined as end-diastolic LV maximum wall thickness (MWT) ≥15mm in Echocardiogram.
- Plan to undergo or recently underwent radionuclide bone scintigraphy and/or SPECT with any of the following radio labelled tracers: 99mTc-DPD or 99mTc-PYP or 99mTc-HMDP.
- Exclusion criteria:
- Etiological diagnosis explaining the LVH (p.e. Sarcomeric HCM, Myeloma, Fabry disease, Sarcoidosis, Any type of amyloidosis (AA, AL, TTR)
- Severe aortic stenosis defined as aortic valve area (AVA) \< 1.0 cm2
Exclusion
Key Trial Info
Start Date :
July 9 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 8 2022
Estimated Enrollment :
812 Patients enrolled
Trial Details
Trial ID
NCT03842163
Start Date
July 9 2018
End Date
June 8 2022
Last Update
February 12 2024
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
The Prince Charles Hospital
Chermside, Australia, 4102
2
The Alfred Department of Cardiology
Melbourne, Australia
3
Medizinische Universität Innsbruck - Universitätsklinik für Innere Medizin III, Kardiologie
Innsbruck, Austria, A-6020
4
Centre Hospitalier Universitaire de Caen
Caen, Cedex, France, 14033